Biology Reference
In-Depth Information
TABLE 12.2 Nucleotide Excision Repair as a Predictive Marker in Human Cancers
Cancer type
Treatment
Repair enzyme
Results
Reference
NSCLC
Cisplatin-based
ERCC1
[
survival with ERCC1 negative
tumors
124
NSCLC
Cisplatin/gemcitabine
ERCC1
Low ERCC1 mRNA level independent
prognostic factor for survival.
125
[
median survival time
NSCLC
Cisplatin/gemcitiabine
ERCC1
Low ERCC1 associated with
median
126
[
OS
NSCLC
Cisplatin-based
ERCC1
CC genotype at codon 118 associated
with
128
median survival compared to
TT or CT genotypes
[
NSCLC
Platinum-based
ERCC1
C8092A polymorphism
e
any copy of
A allele associated with poor outcome
129
NSCLC
Cisplatin-based
ERCC1
C8092A CA genotype associated with
Y
130
DFS and OS than CC genotype. No
association with T19007C SNP and
prognosis
NSCLC
Cisplatin-based
ERCC1
8092A allele associated with
>
2-fold
[
131
grade 3 and 4 GI toxicity
NSCLC
Cisplatin-based
ERCC1
C to A change of Gln504Lys SNP
associated with
132
Y
response to
treatment
NSCLC
Cisplatin-based
ERCC1
No association of C8092A and codon
118 polymorphism and treatment
response
133
NSCLC
Cisplatin-based
ERCC1
Meta-analysis
e
[
RR with wild type
CC genotype of C118T
134
NSCLC
Cisplatin-based
ERCC1
Meta-analysis
e
no association of
C118T or C8092A polymorphism and
prognosis
135
CRC
5-FU/Oxaliplatin
ERCC1
Low mRNA expression associated
with
136
median survival
[
CRC
Irinotecan-based
ERCC1
mRNA associated with good
response to treatment
137
[
CRC
Oxaliplatin/5FU
ERCC1
RR with T/T genotype of T19007C
139
[
CRC
Oxaliplatin/5FU
ERCC1
RR with C/C genotype of T19007C
111, 140
[
CRC
Cx
ERCC1
19007 T
C associated with poor
prognosis
108
>
Gastric
Cisplatin/5FU
ERCC1
Low mRNA level associated with
[
141
survival and response to Cx
Gastric
Oxaliplatin/5FU
ERCC1
No ERCC1 expression associated with
[
142
response to Cx and
[
median OS
Gastric
Cisplatin-based
ERCC1
No association with expression and
survival
143
Esophagus
CRT
ERCC1
[
mRNA expression associated with
poor response to treatment
144
Esophagus
CRT plus surgery
ERCC1
mRNA expression predictor of
risk
145
[
[
of recurrence and
survival
Y
Esophagus
CRT
ERCC1
Expression not association with
response to treatment
146
(Continued)
